4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA 22-25 September 2002.
Highlights are presented from this annual workshop, which was devoted to the investigation of adverse effects associated with antiretroviral therapy for HIV infection. Topics covered included the lipodystrophy syndrome, which encompasses body composition changes (subcutaneous fat wasting, visceral fat accumulation) and metabolic abnormalities (insulin resistance and dyslipidaemia). The relevance of HIV protease inhibitor-induced metabolic abnormalities to cardiovascular disease is discussed. Research in the areas of hyperlactataemia, abacavir hypersensitivity, and bone mineral density in the context of HIV infection is also briefly reviewed.
Nolan
David
D
Centre for Clinical Immunology and Biomedical Statistics, 2nd Floor, North Block, Royal Perth Hospital, Wellington St, Perth 6000, Western Australia. david.nolan@health.wa.gov.au
Christiansen
Frank
F
D000140:Acidosis, Lactic / Q000139:chemically induced / Q000150:complications; D019380:Anti-HIV Agents / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D001823:Body Composition / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects; D006678:HIV / Q000187:drug effects; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D008060:Lipodystrophy / Q000139:chemically induced*; D011480:Protease Inhibitors / Q000627:therapeutic use
D019380:Anti-HIV Agents; D011480:Protease Inhibitors